LP-50 (Intravesical)
Non-Muscle Invasive Bladder Cancer
PreclinicalActive - Preclinical data published at ASCO 2024
Key Facts
Indication
Non-Muscle Invasive Bladder Cancer
Phase
Preclinical
Status
Active - Preclinical data published at ASCO 2024
Company
About Lipella Pharmaceuticals
Lipella Pharmaceuticals leverages its proprietary liposomal delivery platform to develop targeted therapies for mucosal diseases where traditional treatments struggle. The company has a diversified pipeline with LP-10 in Phase 2 trials for oral lichen planus, hemorrhagic cystitis, and oral graft-versus-host disease, and LP-50 in preclinical development for bladder cancer. Their strategy focuses on repurposing proven drugs through the 505(b)(2) regulatory pathway to accelerate development and reduce risk.
View full company profile